APRI: Apricus Biosciences, Inc Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 23, 2:57 PM Apricus Biosciences (APRI -19.4%) tanks after pricing 6M common shares at $2.85, a 13% discount to the closing price of $3.30 on Wednesday. The company also sold warrants to purchase up to 3M shares of common stock and plans to raise a total of $15.8 million net of expenses. The shares of stock and warrants are immediately separable and will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.40 per share. Comment! [Healthcare, On the Move]
Thursday, May 23, 12:45 PM Midday top 10 gainers: ESMC +52%. HIHO +43%. CNIT +23%. RUE +23%. GAME +16%. HPQ +14%. JRJC +13%. PTIX +13%. HSOL +13%. CHYR +13%.
Midday top 10 Losers: RVM -22%. APRI -21%. CRUS -17%. BOSC -15%. NSPR -15%. MTEX -12%. SHIP -11%. IX -10%. EDMC -10%. AERL -10%. 1 Comment [On the Move]
Wednesday, May 22, 6:19 PM Apricus Biosciences (APRI) gets slammed in the post session after anouncing a public offering of common stock and warrants, with a 30-day option to purchase additional shares and warrants to cover over-allotments, if any. Lazard Capital Markets is acting as sole book-running manager. Shares -13% AH. Comment! [Healthcare, On the Move]
Wednesday, May 15, 2:29 PM Apricus Biosciences (APRI +15%) ramps higher today after its board of directors votes to terminate the company's shareholder rights agreement. With the poison pill out of the way, investors appear to be placing bets on a future takeout of the company. Comment! [Healthcare, On the Move]
Tuesday, April 2, 12:16 PM Apricus Biosciences (APRI +2%) moves up today after reporting the sale of some non-core assets: Totect, a marketed, injectable treatment for anthracycline extravasation, and NitroMist, an FDA-approved nitrate vasodilator that treats angina pectoris. Financial details of the sale were not disclosed Comment! [Healthcare, On the Move]
Monday, April 1, 4:50 PM Apricus Biosciences (APRI) moves ahead with its planned divestiture of non-core assets as it sells its extravasation injection Totect to Biocodex and its nitrate vasodilator NitroMist to Mist Pharmaceuticals. The company says it sold the products "in line with their initial up-front purchase price." Comment! [Healthcare]
Monday, March 18, 12:31 PM Apricus Biosciences (APRI -4%) slips today after the company gives an update on corporate activities and announces it's appointed Richard Pascoe, a 20-year veteran in the biopharmaceutical industry, as its new CEO as the company begins development and marketing of Vitaros and Femprox. Comment! [Healthcare, On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Wednesday, November 7, 2012, 12:45 PM Midday top 10 gainers: CALI +89%. SRT +22%. VHC +21%. AMRS +20%. HDY +19%. PKT +16%. FCAL +14%. CNTF +12%. MKTG +10%. SGI +10%. Midday top 10 Losers: QLTY -34%. PLXS -28%. STEC -23%. JRCC -21%. PQ -18%. APRI -18%. FRM -17%. RBCN -17%. PHMD -17%. THQI -17%. Comment!
Tuesday, November 6, 2012, 5:56 PM Apricus Biosciences (APRI) says that its director, president and CEO, Bassam Damaj, Ph.D., has resigned effective immediately, and that Steve Martin, senior vice president and CFO, has been appointed interim CEO. The company also announced that its board has retained an executive recruiting firm to assist in identifying a permanent CEO with pharmaceutical industry experience. Shares -2.3% AH. 1 Comment [Healthcare, On the Move]
Monday, October 1, 2012, 8:00 AM Shares of Apricus Biosciences (APRI) soar 11.1% premarket after the company announces that it will file a new drug submission in Canada for MycoVa in Q4 of 2013. In advanced testing, MycoVa has shown an ability to kill nail fungus and improve the appearance of nails. Comment! [On the Move, Healthcare]
Thursday, September 13, 2012, 9:22 AM Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros. 1 Comment [Healthcare, On the Move]
Thursday, September 13, 2012, 9:10 AM Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%. 1 Comment [On the Move]
Monday, July 16, 2012, 5:38 PM Apricus Biosciences (APRI) files a 3.7M share registration statement. Stock -5.6% AH. 1 Comment [Healthcare, On the Move]
Wednesday, February 15, 2012, 1:01 PM Shares of Apricus Biosciences (APRI +4.4%) kick up a gain after the firm announces that its NexMed subsidiary has signed a collaboration agreement with a division of Novartis (NVS +0.1%) to market Vitarose in Germany. Comment! [On the Move, Healthcare, Global & FX]
Monday, January 9, 2012, 3:22 PM Apricus Bioscience (APRI +4.8%) trades higher after Abbott Laboratories (ABT) signs an exclusive licensing and marketing agreement with the company to sell Vitaros, Apricus' treatment for erectile dysfunction, in Canada. Comment! [Healthcare, On the Move]

APRI Apricus Biosciences, Inc

APRI

Apricus Biosciences, Inc